Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years.

Trial Profile

An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Therapeutic Use
  • Sponsors Ception Therapeutics
  • Most Recent Events

    • 10 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 May 2011 Results presented at the Digestive Disease Week 2011.
    • 30 Sep 2009 Actual patient number (226) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top